Article

ED orally disintegrating tablet now available in the U.S.

An orally disintegrating version of the phosphodiesterase type-5 inhibitor vardenafil hydrochloride (Staxyn), a new FDA-approved treatment for erectile dysfunction, is now available in the United States.

An orally disintegrating version of the phosphodiesterase type-5 inhibitor vardenafil hydrochloride (Staxyn), a new FDA-approved treatment for erectile dysfunction, is now available in the United States.

The new formulation of vardenafil is a 10-mg orally disintegrating tablet taken once per day. Doses should be taken at least 24 hours apart and approximately 1 hour before sexual activity.

The product was developed to address barriers to the use of medications to treat ED by providing a discreet, effective option for patients, said a spokesperson for GlaxoSmithKline, its manufacturer.

Staxyn is not interchangeable with vardenafil film‐coated tablets (Levitra), according to GlaxoSmithKline, because a 10-mg orally disintegrating tablet provides a higher exposure to the active ingredient in the body compared to a 10-mg film‐coated tablet.

The most common side effects are headache, flushing, stuffy or runny nose, indigestion, upset stomach, dizziness, and back pain.

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

© 2025 MJH Life Sciences

All rights reserved.